|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C19H42N.Br |
|||
| Molecular Weight | 364.45 | CAS No. | 57-09-0 | |
| Solubility (25°C)* | In vitro | Water | 100 mg/mL (274.38 mM) | |
| Ethanol | 100 mg/mL (274.38 mM) | |||
| DMSO | 5 mg/mL (13.71 mM) | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Cetrimonium Bromide (CTAB) is a known component of the broad-spectrum antiseptic cetrimide, which is a mixture of different quaternary ammonium salts. |
|---|---|
| In vitro | Cetrimonium Bromide reduces cell viability of FaDu, C666-1, UTSCC-8A, UTSCC-42A, MRC5 cells and GM05757 fibroblasts with EC50 of 2 μM, 3.8 μM, 3.5 μM, 4.2 μM, 11 μM and 18 μM, respectively. Cetrimonium Bromide reduces cell viability of A549 lung and MCF7 breast cancer cells with EC50 of 17 μM and 12 μM. Cetrimonium Bromide (0.5 μM) interacts additively with radiation in a dose-dependent manner to exhibits inhibition effect on the clonogenic survival of FaDu cells. Cetrimonium Bromide results in nuclear condensation and blebbing in FaDu cells, consistent with apoptotic nuclear morphology, which is not observed in CTAB-treated GM05757 fibroblasts. Cetrimonium Bromide reproducibly decreases ATPase activity in a dose-dependent manner in FaDu cells, achieving ∼90% inhibition at 50 μM. Cetrimonium Bromide (5 μM) causes a modest (∼10%), but statistically significant decreases in ATP content in FaDu cells. Cetrimonium Bromide (5 μM) induced apoptosis is significantly suppressed by >50% when CCCP (5 μM) is used to effectively uncouple ΔΨM before Cetrimonium Bromide treatment in FaDu cells. [1] |
| In vivo | Cetrimonium Bromide (5 μM) effectively eliminates the tumor-forming potential of FaDu cells in SCID mice. Cetrimonium Bromide (daily 5 mg/kg i.p. for 5 days) induces a modest reduction in tumor development compared with the vehicle-treatment arm in established FaDu xenograft tumors in SCID mice. [1] |
Protocol (from reference)
Selleck's Cetrimonium Bromide (CTAB) has been cited by 2 publications
| Cetrimonium bromide promotes lipid clearance via TFEB-mediated autophagy-lysosome activation in hepatic cells [ Biochem Cell Biol, 2021, 10.1139/bcb-2020-0570] | PubMed: 33560918 |
| Highly Sensitive Label-Free Detection of Small Molecules with an Optofluidic Microbubble Resonator [Li Z, et al. Micromachines (Basel), 2018, 9(6)] | PubMed: 30424207 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.